Figure 7.
975 Selectively Inhibits MYC-dependent Cancer Cell Viability and the MYC Transcriptional Program.
(A) Anti-proliferative effects of 975 on prostate cancer cells and PC12 following 5 days of treatment.
(B) Dose response effect of 975 on MYC transcriptional activity in E-box luciferase reporter assay compared to CMV-luciferase reporter.
(C) Venn diagram showing overlap of genes regulated in P493–6 cells by: 1) silencing MYC by Tetra 0.1 μg/ml for 48 hr, log fold change > 0.5 from Dang_2018; 2) silencing MYC by Tetra, 0.1 μg/ml for 24 hr, adj-p<0.05, this study; and 3) 975 treatment at 6 μM for 24 hr, adj-p<0.05, from this study.
(D) GO biological process analysis on 975 uniquely regulated genes (1128) in P493–6 cells.
(E) Venn diagram showing overlap of genes regulated by 361 (6 μM, 24 hr) and 975 (8 μM, 24 hr) treatment of PC3 cells from RNA-seq. Genes with adj-p < 0.05, and log fold change > 0.5 were included.
Error bars represent mean ± SEM, n = 4 replicates in (A) and (B), data are representative of two to three independent experiments with similar results. RNA-seq data was assessed in triplicates (C-E).